Table 2 Association testing of PARP-1 polymorphisms with risk of NHL
| NPs | Genotype |
Controls no.(%) |
Cases no.(%) | OR (95% CI) |
|---|---|---|---|---|
| Asp81Asp | GG | 227 (31.5) | 185 (32.5) | 1 |
| GA | 349 (48.4) | 279 (49.0) | 0.99 (0.77-1.27) | |
| AA | 145 (20.1) | 105 (18.5) | 0.90 (0.65-1.24) | |
| GA+AA | 494 (68.5) | 384 (67.5) | 0.96 (0.76-1.21) | |
| Ala284Ala | CC | 424 (58.8) | 357 (62.4) | 1 |
| CT | 264 (36.6) | 189 (33.0) | 0.85 (0.67-1.07) | |
| TT | 33 (4.6) | 26 (4.5) | 0.94 (0.55-1.60) | |
| CT+TT | 297 (41.2) | 215 (37.6) | 0.86 (0.69-1.08) | |
| Lys352Lys | GG | 222 (30.8) | 184 (32.1) | 1 |
| GA | 353 (49.0) | 285 (49.7) | 0.98 (0.76-1.26) | |
| AA | 145 (20.1) | 104 (18.2) | 0.87 (0.64-1.20) | |
| GA+AA | 498 (69.2) | 389 (67.9) | 0.95 (0.75-1.20) | |
| IVS13+118 A>G | AA | 426 (59.2) | 361 (63.0) | 1 |
| AG | 261 (36.3) | 188 (32.8) | 0.85 (0.67-1.07) | |
| GG | 33 (4.6) | 24 (4.2) | 0.86 (0.50-1.48) | |
| AG+GG | 294 (40.8) | 212 (37.0) | 0.85 (0.68-1.06) | |
| Val762Ala | TT | 221 (30.7) | 189 (33.0) | 1 |
| TC | 354 (49.1) | 279 (48.7) | 0.93 (0.72-1.19) | |
| CC | 146 (20.2) | 105 (18.3) | 0.85 (0.62-1.17) | |
| TC+CC | 500 (69.3) | 384 (67.0) | 0.90 (0.71-1.14) |